期刊
NANOMEDICINE
卷 1, 期 1, 页码 17-22出版社
FUTURE MEDICINE LTD
DOI: 10.2217/17435889.1.1.17
关键词
angiogenesis; cancer; imaging; integrin; nanotechnology; targeting
资金
- NATIONAL CANCER INSTITUTE [R01CA108856, T32CA009592] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053718] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER
- NCI NIH HHS [CA108856, CA09592] Funding Source: Medline
- NIAMS NIH HHS [AR053718] Funding Source: Medline
- NINDS NIH HHS [NS45888] Funding Source: Medline
Nanotechnology has advanced greatly in recent years and antiangiogenic therapy is becoming a promising approach for cancer treatment. Therefore, a combination of nanotechnology with antiangiogenic therapy should significantly enhance our ability to treat this deadly disease. alpha(v)beta(3)-integrin has often been used to target 'angiogenically active' tumor endothelium and many nanoparticles have been developed by combining this molecule with other agents for imaging and/or therapy. Development of improved and multifunctional nanoparticles is in progress for the enhancement of imaging, targeting, delivery and other processes. Modification for clinical use has been challenging. Concerns remain regarding safety, stability and tissue targeting of the particles, yet significant progress has been made. in this review, studies targeting 'angiogenically active' tumor endothelium using nanoparticles are discussed. The number of studies using multifunctional nanotechnology in tumor angiogenesis is still limited; however, significant. advancement in this area is expected to come in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据